Inflammation/Immunology

Levomilnacipran-d₁₀ ((1S,2R)-Milnacipran-d₁₀) hydrochloride is deuterium labeled Levomilnacipran hydrochloride (HY-B0168B). Levomilnacipran ((1S,2R)-Milnacipran) hydrochloride is the enantiomer of Milnacipran (HY-B0168) and a strong substrate of P-gp that can cross the blood-brain barrier. Levomilnacipran hydrochloride is a serotonin and norepinephrine reuptake inhibitor, with IC₅₀ values of 10.5 nM and 19.0 nM, and K_i values of 92.2 nM and 1.2 nM for human norepinephrine transporter (NET) and serotonin transporter (SERT), respectively. Levomilnacipran hydrochloride has antidepressant and anxiolytic activities. Levomilnacipran hydrochloride can be used for the research of depression.

Anti-CDH19 Antibody is a monoclonal antibody that targets CDH19. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-CDH19 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).

YJC-10592 is an orally active CCR-2 antagonist. YJC-10592 binds to HAS. YJC-10592 can be used in the research of asthma and idiopathic dermatitis.

24-O-Acetyllycoclavanol (compound 1) is a triterpenoid anti-inflammatory agent that selectively targets the NF-κB and ERK1/2 signaling pathways. It exerts its anti-inflammatory activity by inhibiting lipopolysaccharide (LPS)-induced inducible nitric oxide synthase (iNOS) and COX-2 expression, reducing the production of inflammatory mediators such as nitric oxide (NO), IL-1β, and IL-8. 24-O-Acetyllycoclavanol can be used in research related to inflammatory bowel disease (IBD). 24-O-Acetyllycoclavanol can be biologically isolated from the ethyl acetate extract of Lycopodium clavatum.

Anti-Notch4 Antibody is a monoclonal antibody targeting Notch4. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-Notch4 Antibody, please refer to Human IgG2 kappa, Isotype Control (HY-P99002).

Anti-NGLY1 Antibody is a monoclonal antibody that targets NGLY1. Anti-NGLY1 Antibody can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-NGLY1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).

NOX4-IN-1 (Compound 14m) is the inhibitor for NADPH oxidase 4 (NOX4), and blocks the generation of ROS. NOX4-IN-1 inhibits TGF-β1/Smad signaling pathway, decreases the expression of fibrosis-related proteins. NOX4-IN-1 inhibits the cell migration of NRK-49F.

Cevolisiran sodium scrambled negative control is the sequence scrambled negative control of Cevolisiran sodium.

Brp-201 is considered as a promising therapeutic target for the next generation of anti-inflammatory drugs in the research of inflammatory diseases. It is a new, effective and selective inhibitor of mPGES-1 with an IC₅₀ value of 0.42 μM.

RPR-200765A methanesulfonate is an orally active p38 MAPK inhibitor with an IC₅₀ of 0.050 μM. RPR-200765A methanesulfonate shows weak activity against Lck, and exhibits no significant activity against ERK, ZAP70 or SYK. It inhibits the production of TNFα and can be used in the research of inflammatory diseases.

Alismanol M is a farnesoid X receptor (FXR) agonist with an EC₅₀ value of 50.25 μM. Alismanol M is a protostane-type triterpenoid that can be isolated from the rhizome of Alisma orientale. Alismanol M can be used for the research of cholestasis and nonalcoholic steatohepatitis.

Chondrocyte‑affinity peptide (CAP) is a dodecapeptide that exhibits targeted binding activity toward chondrocytes and can penetrate the dense cartilage matrix. Conjugation of Chondrocyte‑affinity peptide with polyethyleneimine (PEI) mediates the enrichment of gene vectors in chondrocytes. Chondrocyte‑affinity peptide can be applied in research related to targeted drug delivery to chondrocytes.

Cyclic peptide P1-1 is a high-potent GPR55 antagonist. Cyclic peptide P1-1 antagonizes GPR55 and suppresses collagen secretion. Cyclic peptide P1-1 reduces ROS production, attenuates ER stress, and inhibits mitochondria-associated Apoptosis. Cyclic peptide P1-1 inhibits the expression of α-SMA and COL1α. Cyclic peptide P1-1 ameliorates CCl₄ (HY-Y0298)-induce and MCD-diet-induce acute liver inflammation and fibrosis.

CFTR corrector 13 (SVQ18) is a cystic fibrosis transmembrane conductance regulator (CFTR) corrector (EC₅₀=3.14 μM). CFTR corrector 13 enhances the function of CFTR channels, especially when used in combination with Lumacaftor (HY-13262), it can produce a dose-dependent increase in CFTR function. CFTR corrector 13 can be used in the study of cystic fibrosis (CF) and other CFTR-related diseases.

AC-430 is a JAK2 inhibitor. AC-430 can be used in the research of rheumatoid arthritis.

Typhaneoside (Standard) is the analytical standard of Typhaneoside. This product is intended for research and analytical applications. Typhaneoside, extracted from Typha angustifolia L., Typhaneoside can inhibit the excessive autophagy of hypoxia/reoxygenation cells and increase the phosphorylation of Akt and mTOR. Typhaneoside has certain effects on the cardiovascular system, including lowering blood lipid levels, promoting antiatherosclerosis activities, as well as improving immune and coagulation function.

DC360 is a synthetic retinoid analogue of all-trans retinoic acid (ATRA) which induces RARβ expression. DC360 can be utilized in characterization of retinoid signalling pathways.

PTPRO-IN-1 is a selective, orally active PTPRO inhibitor with an IC₅₀ of 0.16 μM. PTPRO-IN-1 exhibits IC₅₀ values of 2.4 μM, 2.33 μM and 2.13 μM against PTPN22, PTP1B and PTPRT, respectively, and shows almost no inhibitory activity against STEP/SSH2. PTPRO-IN-1 inhibits the TLR4/NF-κB signaling pathway in macrophages, ameliorates colonic pathological conditions and suppresses the secretion of pro-inflammatory cytokines by T cells. PTPRO-IN-1 can be used for the research of inflammatory bowel disease.

Glucosamine-biotin adduct is a hapten and can be conjugated to hsIgG.

IRAK1-IN-1 (compound B8) is an orally active IRAK1 inhibitor. IRAK1-IN-1 inhibits the release of IL-6 with the IC₅₀ values of 4.57 μM and 6.51 μM on mouse cells J774A. 1 and human cells THP-1, respectively. IRAK1-IN-1 alleviats LPS (HY-D1056)-induced acute lung injury (ALI) and DSS(HY-116282C)-induced colitis in mice.